Saudi Journal of Kidney Diseases and Transplantation

ORIGINAL ARTICLE
Year
: 1994  |  Volume : 5  |  Issue : 1  |  Page : 12--16

Potentiation of the Action of Warfarin by Bezafibrate in Patients with the Nephrotic Syndrome


Abdul-Kareem Al-Momen, Huda Al-Abdul-Kareem 
 Division of Hematology, Department of Medicine, College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia

Correspondence Address:
Abdul-Kareem Al-Momen
Department of Medicine, College of Medicine, P.O. Box 2925, Riyadh 11461
Saudi Arabia

Nephrotic syndrome is associated with thromboembolic disease due to a variety of factors. In addition, therapy with anticoagulants is often met with poor response, to warfarin for example, which occurs due to factors such as reduced serum albumin and binding sites, increased free warfarin with rapid metabolism and clearance, and possible urinary loss. Bezafibrate is known to augment the action of warfarin and improve coagulation profile. In this article, we present three cases with severe nephrotic syndrome associated with hyperfibrinogenemia, hypercholesterolemia and thromboembolic disease who showed poor response to therapy with warfarin. They showed improvement of their coagulation profile upon concomitant administration of bezafibrate.


How to cite this article:
Al-Momen AK, Al-Abdul-Kareem H. Potentiation of the Action of Warfarin by Bezafibrate in Patients with the Nephrotic Syndrome.Saudi J Kidney Dis Transpl 1994;5:12-16


How to cite this URL:
Al-Momen AK, Al-Abdul-Kareem H. Potentiation of the Action of Warfarin by Bezafibrate in Patients with the Nephrotic Syndrome. Saudi J Kidney Dis Transpl [serial online] 1994 [cited 2022 May 27 ];5:12-16
Available from: https://www.sjkdt.org/article.asp?issn=1319-2442;year=1994;volume=5;issue=1;spage=12;epage=16;aulast=Al-Momen;type=0